HAG
MACK

HighPoint Advisor Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

HighPoint Advisor Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,078
Closed -$344K – 330
2016
Q2 		$344K Buy
1,078
+357
+50% +$19.4K 0.12% 184
2016
Q1 		$251K Buy
+721
New +$37.6K 0.15% 154

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

HighPoint Advisor Group's MACK Position: Q3 2016 in Review

HighPoint Advisor Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2016, closing a stake of 1,078 shares — an estimated $344K sold.

HighPoint Advisor Group first reported a position in MACK in Q1 2016 and held it in 2 quarters. The position peaked at $344K in Q2 2016. 128 funds tracked by Wall St. Rank hold MACK as of Q3 2016.

  • HighPoint Advisor Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • HighPoint Advisor Group sold 1,078 Merrimack Pharmaceuticals, Inc. shares in Q3 2016, an estimated $344K.
  • HighPoint Advisor Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2016 and held it in 2 quarters.
  • HighPoint Advisor Group's Merrimack Pharmaceuticals, Inc. position peaked at $344K in Q2 2016.
  • 128 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2016.

Based on HighPoint Advisor Group's 13F filing for Q3 2016, filed 21 Nov 2016.